Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

279

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

October 15, 2021

Study Completion Date

September 27, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

EuCorVac-19

Two intramuscular doses (0.5mL per dose) at 3-week interval

OTHER

Normal Saline

Two intramuscular doses (0.5mL per dose) at 3-week interval

Trial Locations (1)

The Catholic University of Eunpyeong St.Mary's Hospital, Seoul